Absci Corporation (ABSI)
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABSI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.30B
- EPS (TTM)
- -$0.79
- Dividend yield
- None
- 52-week range
- 2.24 – 12.55
- Day range
- 7.45 – 8.14
- Volume / Avg
- 4.74M / 4.08M
- Beta
- —
- Shares outstanding
- 172.75M
52-week range
ABSI stock today
Absci (ABSI) closed at $7.51 on Nov 20, down 7.97% (-$0.65), versus the S&P 500's 3.70% decline. Shares are 40.1% below their 52-week high of $12.55, set on Oct 29, 2026 and 235.3% above the 52-week low of $2.24, in the middle of the past year's range. ABSI is up 115.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 156.3%.
Absci has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Absci
Company profileAbsci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Sean McClain
- Headquarters
- Vancouver, WA
- Employees
- 140
- IPO year
- 2021
- Website
- absci.com
Financial highlights
Full financialsIn fiscal 2025, Absci generated $2.8 million in revenue, down 38.2% from fiscal 2024, its first annual decline since 2024. Absci reported a net loss of $115.2 million, compared with a loss of $103.1 million a year earlier. Operating margin was -4297.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.80M | $4.53M | $5.72M | $5.75M | $4.78M |
| Growth | -38.24% | -20.71% | -0.50% | +20.18% | +0.04% |
| Net income | $-115.18M | $-103.11M | $-110.57M | $-104.90M | $-100.96M |
| EPS (diluted) | $-0.84 | $-0.94 | $-1.20 | $-1.15 | $-2.08 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$15.09+100.93%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.17 vs $-0.14
- Surprise
- -21.43%
ABSI news
All ABSI news- Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 startSeeking Alpha
- Absci (ABSI) Q3 2026 Earnings Call TranscriptNasdaqABSI, LEN.B
- Absci Corp Q3 Sales DeclineNasdaqABSI, BF.A
- Absci GAAP EPS of -$0.19 in-line, revenue of $0.3M misses by $0.28MSeeking Alpha
- Absci Reports Business Updates and Third Quarter 2026 Financial and Operating ResultsGlobeNewswire
- Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader PipelineGlobeNewswire
- Absci Q3 2026 Earnings PreviewSeeking Alpha
- Jefferies Initiates Coverage of Absci with BuyNasdaqABSI, MOG.B
Absci peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs ABSI |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs ABSI |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs ABSI |
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs ABSI |
| BIAFbioAffinity Technologies Inc. | 1.65 | -10.81% | $3.00M | vs ABSI |
| ISPCiSpecimen Inc. | 0.4563 | -13.58% | $2.64M | vs ABSI |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs ABSI |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs ABSI |
Indexes, lists and sector
Absci stock FAQ
What is Absci's stock price today?
ABSI last traded at $7.51 as of Nov 20, 4:00 PM EST, down 7.97% on the day. Prices are delayed at least 15 minutes.
Who is Absci's CEO?
Mr. Sean McClain is the chief executive officer of Absci Corporation, which has about 140 employees.
What is the ABSI 52-week high?
The 52-week high for ABSI is $12.55 and the 52-week low is $2.24. The stock is currently 40.1% below its high.